UroGen Pharma (URGN) Tops Q1 EPS by 12c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments
May 13, 2021 7:30 AM EDTJelmyto® net product revenue of $7.5 million for the first quarter of 2021 New patient starts in March and April of 2021 increased 100% and 165%, respectively, compared to new patient starts in January 2021 Phase 3 ATLAS trial enrollment ongoing with new sites activated in Europe Active platform expansion in immuno-oncology with commencement of strategic collaborations with leading academic institutions Conference call and webcast to be held today at 8:30 AM ET
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company... More
